Application effect of rivaroxaban in the prevention of PVT after splenectomy for liver cirrhosis
Objective To explore the application effect of rivaroxaban in the prevention of portal vein thrombosis(PVT)after splenectomy for liver cirrhosis.Methods A total of 120 patients who underwent splenectomy for liver cirrhosis from February 2019 to February 2021 were randomly divided into control group and observation group,with 60 cases in each group.Both groups were given laparoscopic splenectomy,the control group was treated with aspirin combined with dipyridamole,and the observation group was treated with rivaroxaban.The therapeutic effects of the two groups were compared.Results After treatment,the activated partial thromboplastin time(APTT)and prothrombin time(PT)in the observation group were longer than those in the control group,the levels of D-dimer(D-D),platelet count(PLT)and endothelin(ET)were lower than those in the control group,and the differences were statistically significant(P＜0.05).After treatment,the diameter of portal vein in the observation group was smaller than that in the control group,the maximum blood flow velocity and average blood flow velocity were higher than those in the control group,and the differences were statistically significant(P＜0.05).The incidence of PVT in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05);the Yerdel grade of the observation group was lower than that of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse events between the two groups(P＞0.05).Conclusion Rivaroxaban can effectively prevent PVT formation in patients with liver cirrhosis after splenectomy,with high safety and certain promotion value.
NETL
